Redefining First-Line EGFR+ NSCLC with Subcutaneous Amivantamab & LazertinibByNicolas Girard, MD, PhDApril 2nd 2026
Precision or Urgency? Managing PD-L1 Testing in Metastatic NSCLCByTargeted Oncology StaffMarch 26th 2026
Bevacizumab Biosimilar HD204 Meets Primary End Point in Phase 3 NSCLC TrialBySabrina SeraniMarch 25th 2026